In ₹ Crore except Per Share Latest Annual	NATCAPSUQ FY26	NECLIFE FY26	AAREYDRUGS FY26	BALPHARMA FY26	Peer Average
Valuation — at last close
P/E	—	—	77.73×	◆ 21.82×	49.77×
P/B	0.64×	◆ 0.35×	2.04×	1.67×	1.35× -53%
EV/EBITDA	◆ -169.48×	-1.25×	49.64×	9.13×	19.17× -984%
Market Cap	₹142 Cr	₹201 Cr	₹307 Cr	₹137 Cr	₹215 Cr -34%
Growth
Revenue CAGR 3Y	—	-81.73%	◆ 96.26%	0.81%	5.11%
Revenue CAGR 5Y	—	-64.04%	—	◆ 4.46%	-29.79%
Net Income CAGR 3Y	—	—	◆ 100.20%	34.12%	67.16%
Revenue YoY (latest Q)	7.76%	-99.99%	-56.34%	◆ 34.53%	-40.60% +119%
Net Income YoY (latest Q)	-2.93%	75.65%	-25.36%	◆ 445.66%	165.32% -102%
Profitability
EBITDA Margin	-0.83%	—	1.52%	◆ 10.24%	5.88% -114%
Net Income Margin	-13.17%	-3152.45%	0.84%	◆ 2.03%	-1049.86% +99%
Return on Common Equity	-7.51%	-38.08%	2.75%	◆ 7.87%	-9.15% +18%
Return on Capital Employed	-6.12%	-7.53%	2.94%	◆ 17.17%	4.19% -246%
Return on Assets	-5.85%	-21.95%	1.48%	◆ 1.78%	-6.23% +6%
Credit & Quality
Total Debt/Equity	0.49×	◆ 0.00×	0.33×	1.94×	0.76× -35%
Interest Coverage	-1.71×	-1.69×	0.86×	◆ 1.24×	0.14× -1351%
Scale — latest FY
Revenue / Total Income	₹187 Cr	₹0 Cr	₹472 Cr	₹312 Cr	₹261 Cr -28%
Net Income	−₹24.7 Cr	−₹293 Cr	₹4 Cr	₹6.3 Cr	−₹94.2 Cr +74%
Total Assets	₹424 Cr	₹622 Cr	₹297 Cr	₹376 Cr	₹431 Cr -2%
EPS	₹-23.84	₹-13.4	₹1.39	₹3.95	₹-2.69 -787%
Book Value per Share	₹213.39	₹29.97	₹52.86	₹51.65	₹44.83 +376%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.